| Literature DB >> 30291042 |
F Campanile1, D Bongiorno2, G Mongelli2, G Zanghì3, S Stefani2.
Abstract
This study investigated the in vitro susceptibility of ceftobiprole and its potential synergistic activity in combination with other antimicrobials against 46 selected Gram-positive pathogens displaying resistance or decrease susceptibility to several drugs. The gradient-cross method was used to assess synergism between ceftobiprole and daptomycin, levofloxacin, linezolid, rifampicin and piperacillin/tazobactam. Time-kill curves were performed for seven representative isolates. Ceftobiprole MICs ranged from 0.25-6 mg/L for staphylococci; 4-≥32 mg/L for Enterococcus faecalis, and 0.38-≥32 mg/L for E. faecium. Ceftobiprole plus daptomycin was synergistic against all isolates. Ceftobiprole plus linezolid was synergistic against 4 isolates belonging to different species. Ceftobiprole plus levofloxacin was synergistic only against enterococci. In conclusion, ceftobiprole exhibited a potent in vitro antibacterial activity and exhibited synergy with daptomycin against all Gram-positive isolates, despite their antibiotic resistance phenotypes. The use of ceftobiprole in combination may provide a promising alternative therapy for the treatment of resistant Gram-positive infections.Entities:
Keywords: Ceftobiprole; Combinations; Gram-positive; Time-kill curves
Mesh:
Substances:
Year: 2018 PMID: 30291042 DOI: 10.1016/j.diagmicrobio.2018.07.015
Source DB: PubMed Journal: Diagn Microbiol Infect Dis ISSN: 0732-8893 Impact factor: 2.803